For the year ending 2025-12-31, CTNM has $276,642K in assets. $15,653K in debts. $75,603K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 75,603 | |||
| Marketable securities | 187,293 | |||
| Prepaid expenses and other current assets | 5,021 | |||
| Total current assets | 267,917 | |||
| Property and equipment, net | 830 | |||
| Other long-term assets | 256 | |||
| Operating lease right-of-use assets | 7,639 | |||
| Total assets | 276,642 | |||
| Accounts payable | 1,016 | |||
| Accrued expenses | 6,387 | |||
| Current portion of operating lease liabilities | 2,341 | |||
| Total current liabilities | 9,744 | |||
| Operating lease liabilities, net of current portion | 5,909 | |||
| Total liabilities | 15,653 | |||
| Common stock-Common Class A | 31 | |||
| Common stock-Common Class B | 6 | |||
| Additional paid-in-capital | 438,072 | |||
| Accumulated deficit | -177,380 | |||
| Accumulated other comprehensive income | 260 | |||
| Total stockholders equity | 260,989 | |||
| Total liabilities and stockholders equity | 276,642 | |||
Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics, Inc. (CTNM)